ORIC Pharmaceuticals, Inc. (ORIC)
After hours:
| Previous Close | 9.12 |
| Open | 9.19 |
| Bid | 9.55 x 100 |
| Ask | 9.65 x 100 |
| Day's Range | 9.02 - 9.72 |
| 52 Week Range | 6.33 - 16.65 |
| Volume | |
| Avg. Volume | 447,687 |
| Market Cap | 676.738M |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.82 |
| Earnings Date | Nov 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.73 |
GlobeNewswireORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference Announced clinical collaborations with multiple strategic partners to support ongoing trial evaluating ORIC-944 in combination with AR inhibitors for the treatment of prostate cancer Cash and investments of $282.4 million expected to fund operating plan into late 2026 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO,
- GlobeNewswire
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in November: Guggenheim’s Inaugural Healthcare Innovation Conference – Participating in a fireside chat on Monday, November 11, 2024, at 10:30 a.m. ETJefferies London Healthca
